{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-084991","form_type":"8-K","ticker":null,"cik":"0001673772","company_name":"RAPT Therapeutics, Inc.","filed_at":"2024-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.053962+00:00","generated_at":"2026-05-31T19:05:25.407912+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"RAPT Therapeutics cuts 40% of workforce (47 employees) to conserve cash, expects $0.9M charge","bullets":["Board approved workforce reduction of 47 people, representing ~40% of total headcount.","Company expects ~$0.9 million in restructuring charges from severance, benefits, and related costs.","Majority of cash payments and execution expected by end of Q3 2024.","Severance benefits contingent on affected employees signing general release of claims."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-084991","json":"https://secwatch.observer/filing/0000950170-24-084991.json","markdown":"https://secwatch.observer/filing/0000950170-24-084991.md","text":"https://secwatch.observer/filing/0000950170-24-084991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1673772/000095017024084991/0000950170-24-084991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1673772/000095017024084991/rapt-20240716.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T19:05:25.407912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"998147db4eaec8efaf017826d15c5e23f91f2a93","claim":"RAPT Therapeutics, Inc. announced a restructuring with charges of approximately $0.9 million (47 people, or approximately 40% of the Company's existing headcount).","evidence_excerpt":"for severance benefits is contingent upon such employee’s execution of a general release of claims against the Company. The Company estimates that it will incur approximately $0.9 million in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance payments, benefits and related costs. The","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1673772/000095017024084991/0000950170-24-084991-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.9 million"},{"label":"Headcount","value":"47 people, or approximately 40% of the Company's existing headcount"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}